Alternate Day Micafungin: A PK Study in Pediatric Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the pharmacokinetics of micafungin when it is given on an every other day schedule. The study will determine if every other day micafungin will provide drug exposure equivalent to daily dosing while reducing administration costs and improving patient convenience. Fifteen patients will be enrolled on this study. Blood samples for PK measurements will be obtained for 48 hours following a single dose of micafungin (3 mg/kg).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

NCT02057289

Immunocompromised Bone Marrow Transplant Cancer

TERMINATED PHASE1

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

NCT00818584

Candida

COMPLETED PHASE1

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335

Oropharyngeal Candidiasis Candidemia Invasive Candidiasis +1 more

COMPLETED PHASE1

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

NCT01686607

Systemic Fungal Infections

COMPLETED

Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

NCT03421002

Candidiasis, Systemic Candida Meningitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disseminated fungal infection is a major cause of morbidity and mortality in immunocompromised children. Many of the drugs used for fungal prophylaxis have been associated with kidney and liver toxicity. Also, breakthrough infections have been reported with the use of some of the oral agents due to poor oral absorption. An alternative approach is the use of intravenous micafungin for fungal prophylaxis. Micafungin has a distinct advantage due to its better safety profile, specifically in terms of liver and kidney toxicity. Currently, children who receive micafungin are given daily dosing. This study will examine the pharmacokinetics of micafungin when it is given on an every other day schedule. It will examine whether every other day micafungin will provide drug exposure equivalent to daily dosing while reducing administration costs and improving patient convenience. Both animal and adult human data support the use of this approach. Fifteen patients will be enrolled on this study and will be given a single dose of micafungin (3 mg/kg). Blood samples will be drawn for pharmacokinetic measurements after administration of micafungin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fungal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Micafungin

3 mg/kg given once

Group Type OTHER

Micafungin

Intervention Type DRUG

3 mg/kg IV once over 1 hour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micafungin

3 mg/kg IV once over 1 hour

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MYCAMINE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients who are at risk for fungal infection and require prophylaxis.
* Age ≤ 10 years excluding neonates
* Children must have an indwelling venous access device
* Patients with adequate organ function (documented within 2 weeks prior to start of micafungin): creatinine \< 2 times upper limit normal; ALT, AST and total bilirubin ≤ 3 times upper limit normal

Exclusion Criteria

* Patients who are \< 28 days old (neonates) or \> 10 years of age
* Patients who have history of past or evidence of active fungal disease (by either radiological studies or biopsy proven) or are being treated for presumed fungal infection.
* Patients who have history of allergy to micafungin or other echinocandin preparations, such as Caspofungin or Anidulafungin.
* Patients who have received micafungin or other echinocandin preparations in the previous two weeks.
* Patients receiving antifungal prophylaxis other than Fluconazole at the time of enrollment.
* Failure to sign informed consent, or inability to undergo informed consent process.
* Not medically advisable to obtain the specimens necessary.

Minimum Eligible Age

29 Days

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No